Peddock Capital Advisors LLC Raises Holdings in Zoetis Inc. (NYSE:ZTS)

Peddock Capital Advisors LLC boosted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 1.4% in the 4th quarter, Holdings Channel reports. The fund owned 7,562 shares of the company’s stock after buying an additional 107 shares during the period. Peddock Capital Advisors LLC’s holdings in Zoetis were worth $1,232,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of the stock. State Street Corp grew its stake in shares of Zoetis by 0.5% during the 3rd quarter. State Street Corp now owns 19,779,344 shares of the company’s stock worth $3,864,488,000 after purchasing an additional 95,856 shares during the period. Geode Capital Management LLC grew its position in Zoetis by 1.8% during the third quarter. Geode Capital Management LLC now owns 10,427,760 shares of the company’s stock valued at $2,030,813,000 after buying an additional 185,364 shares during the period. Mizuho Securities USA LLC increased its holdings in Zoetis by 13,726.9% in the third quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock valued at $950,524,000 after buying an additional 4,829,815 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Zoetis by 5.3% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,896,106 shares of the company’s stock worth $761,221,000 after acquiring an additional 194,542 shares during the period. Finally, Clearbridge Investments LLC boosted its stake in shares of Zoetis by 5.8% during the 2nd quarter. Clearbridge Investments LLC now owns 3,044,384 shares of the company’s stock worth $527,774,000 after acquiring an additional 166,517 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Trading Up 1.8 %

NYSE ZTS traded up $2.99 on Monday, reaching $166.31. 2,305,990 shares of the company were exchanged, compared to its average volume of 2,469,057. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.53. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. The business’s fifty day moving average price is $171.71 and its 200 day moving average price is $180.29. The stock has a market capitalization of $75.03 billion, a P/E ratio of 31.26, a price-to-earnings-growth ratio of 2.91 and a beta of 0.89.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The firm had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.29 billion. During the same period last year, the business earned $1.36 earnings per share. Zoetis’s revenue was up 11.6% compared to the same quarter last year. Analysts forecast that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be given a dividend of $0.50 per share. The ex-dividend date is Tuesday, January 21st. This is a boost from Zoetis’s previous quarterly dividend of $0.43. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.20%. Zoetis’s dividend payout ratio (DPR) is currently 37.59%.

Analyst Ratings Changes

A number of research firms recently weighed in on ZTS. Leerink Partners started coverage on Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target for the company. UBS Group began coverage on shares of Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price target for the company. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Stifel Nicolaus cut their target price on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Finally, JPMorgan Chase & Co. raised their price target on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $211.89.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.